Lin Chia-Chen, Su Shih-Huan, Jeng Wen-Juei, Huang Chien-Hao, Teng Wei, Chen Wei-Ting, Chen Yi-Cheng, Lin Chun-Yen, Sheen I-Shyan
School of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan.
Division of Hepatology, Department of HepatoGastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan.
BMC Gastroenterol. 2017 Dec 29;17(1):169. doi: 10.1186/s12876-017-0724-4.
Chemokines/cytokines play important roles in the pathogenesis of chronic hepatitis C (CHC). However, their clinical characteristics and implications in treatment responses to pegylated interferon plus ribavirin treatment (PegIFN/RBV) have not been fully illustrated yet. In this study, we intended to investigate the possible predictability of serum chemokines/cytokines on the treatment response in Taiwanese of CHC, genotype-1 (GT-1).
60 Patients with GT-1 CHC infection who had been treated with PegIFN/RBV were enrolled, including 27 (45%) with sustained virological response (SVR), 11 (18%) with relapse after 48 weeks of treatment and 22 (37%) non-response (NR). Clinical parameters, seven chemokines/cytokines, CCL3, CCL4, CXCL9, CXCL10, CXCL11, IL-10 and IFN-γ, and genotypes of rs12979860, the single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) were analyzed for their relationship to treatment response.
Baseline serum levels of CXCL10, CXCL11, CCL3 and CCL4 were significantly higher in NR group while comparing with non-NR group. (CXCL10: p = 0.001; CXCL11: p < 0.001; CCL3: p = 0.006; CCL4: p = 0.005). However, only rs12979860 CC genotype was the independent factors for NR in GT-1 CHC infection (OR, 8.985; p = 0.008). In addition, baseline serum level of CCL4 was found to be the only independent factor for NR in GT-1 CHC patients with favorable IL28B genotype (OR, 1.134; p = 0.039).
IL28B genotype is the predictor for NR in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for NR in GT-1 CHC patients with favorable IL28B genotype.
趋化因子/细胞因子在慢性丙型肝炎（CHC）的发病机制中发挥重要作用。然而，它们的临床特征以及对聚乙二醇干扰素联合利巴韦林治疗（PegIFN/RBV）反应的影响尚未完全阐明。在本研究中，我们旨在探讨血清趋化因子/细胞因子对台湾CHC 1型（GT-1）患者治疗反应的可能预测性。
纳入60例接受PegIFN/RBV治疗的GT-1 CHC感染患者，其中27例（45%）获得持续病毒学应答（SVR），11例（18%）在治疗48周后复发，22例（37%）无应答（NR）。分析临床参数、七种趋化因子/细胞因子（CCL3、CCL4、CXCL9、CXCL10、CXCL11、IL-10和IFN-γ）以及白细胞介素-28B（IL28B）的单核苷酸多态性（SNP）rs12979860的基因型与治疗反应的关系。
与非NR组相比，NR组基线血清CXCL10、CXCL11、CCL3和CCL4水平显著更高。（CXCL10：p = 0.001；CXCL11：p < 0.001；CCL3：p = 0.006；CCL4：p = 0.005）。然而，只有rs12979860 CC基因型是GT-1 CHC感染中NR的独立因素（OR，8.985；p = 0.008）。此外，在具有良好IL28B基因型的GT-1 CHC患者中，发现CCL4基线血清水平是NR的唯一独立因素（OR，1.134；p = 0.039）。
IL28B基因型是接受PegIFN/RBV治疗的GT-1 CHC患者NR的预测指标，而CCL4基线血清水平是具有良好IL28B基因型的GT-1 CHC患者NR的唯一预测指标。
